Bausch Health Companies Inc. Deferred Tax Liabilities, Gross
Bausch Health Companies Inc. (BHC) had Deferred Tax Liabilities, Gross of $379.00 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-19
- 2025-12-31: Deferred Tax Liabilities, Gross $379.00M.
- 2024-12-31: Deferred Tax Liabilities, Gross $396.00M.
- 2023-12-31: Deferred Tax Liabilities, Gross $386.00M; Deferred Tax Liabilities, Gross as first filed $362.00M.
- 2022-12-31: Deferred Tax Liabilities, Gross $390.00M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $379.00M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $396.00M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $386.00M 10-K · filed 2025-02-20 | $362.00M 10-K · filed 2024-02-22 |
| 2022-12-31 | $390.00M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $342.00M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $390.00M 8-K · filed 2022-05-11 | |
| 2019-12-31 | $150.00M 8-K · filed 2021-05-04 | |
| 2018-12-31 | $276.00M 10-K · filed 2020-02-19 | |
| 2017-12-31 | $2.17B 10-K · filed 2019-02-20 | |
| 2016-12-31 | $6.37B 8-K · filed 2018-08-10 | |
| 2015-12-31 | $7.50B 10-K · filed 2017-03-01 | $7.50B 10-K · filed 2016-04-29 |
| 2014-12-31 | $3.16B 10-K · filed 2016-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |